321 related articles for article (PubMed ID: 23537191)
21. Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?
Scichilone N; Benfante A; Bocchino M; Braido F; Paggiaro P; Papi A; Santus P; Sanduzzi A
Pulm Pharmacol Ther; 2015 Apr; 31():63-7. PubMed ID: 25724817
[TBL] [Abstract][Full Text] [Related]
22. Inhaled drug delivery in the hands of the patient.
Lavorini F
J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):414-8. PubMed ID: 25238005
[TBL] [Abstract][Full Text] [Related]
23. Optimising Inhaled Pharmacotherapy for Elderly Patients with Chronic Obstructive Pulmonary Disease: The Importance of Delivery Devices.
Lavorini F; Mannini C; Chellini E; Fontana GA
Drugs Aging; 2016 Jul; 33(7):461-73. PubMed ID: 27216613
[TBL] [Abstract][Full Text] [Related]
24. Misuse and/or treatment delivery failure of inhalers among patients with asthma or COPD: A review and recommendations for the conduct of future research.
Mahon J; Fitzgerald A; Glanville J; Dekhuijzen R; Glatte J; Glanemann S; Torvinen S
Respir Med; 2017 Aug; 129():98-116. PubMed ID: 28732842
[TBL] [Abstract][Full Text] [Related]
25. Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives.
Sharafkhaneh A; Wolf RA; Goodnight S; Hanania NA; Make BJ; Tashkin DP
COPD; 2013 Aug; 10(4):482-92. PubMed ID: 23875742
[TBL] [Abstract][Full Text] [Related]
26. Comparative Study of Inhaler Device Handling Technique and Risk Factors for Critical Inhaler Errors in Korean COPD Patients.
Jang JG; Chung JH; Shin KC; Jin HJ; Lee KH; Ahn JH
Int J Chron Obstruct Pulmon Dis; 2021; 16():1051-1059. PubMed ID: 33907392
[TBL] [Abstract][Full Text] [Related]
27. FIDEPOC: Consensus on Inspiratory Flow and Lung Deposition as Key Decision Factors in COPD Inhaled Therapy.
González-Torralba F; Baloira A; Abad A; Fuster A; García-Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL
Int J Chron Obstruct Pulmon Dis; 2022; 17():1005-1015. PubMed ID: 35547784
[TBL] [Abstract][Full Text] [Related]
28. Technical Evaluation of Soft Mist Inhaler Use in Patients with Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study.
Zhang W; Xu L; Gao S; Ding N; Shu P; Wang Z; Li Y
Int J Chron Obstruct Pulmon Dis; 2020; 15():1471-1479. PubMed ID: 32606655
[TBL] [Abstract][Full Text] [Related]
29. [The choice of inhalation device: A medical act].
Devillier P; Salvator H; Roche N
Rev Mal Respir; 2015 Jun; 32(6):599-607. PubMed ID: 25433462
[TBL] [Abstract][Full Text] [Related]
30. Optimising inhaler technique in chronic obstructive pulmonary disease: a complex issue.
Riley J; Krüger P
Br J Nurs; 2017 Apr; 26(7):391-397. PubMed ID: 28410043
[TBL] [Abstract][Full Text] [Related]
31. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.
Hodder R; Price D
Int J Chron Obstruct Pulmon Dis; 2009; 4():381-90. PubMed ID: 19888356
[TBL] [Abstract][Full Text] [Related]
32. New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.
Ninane V; Vandevoorde J; Cataldo D; Derom E; Liistro G; Munghen E; Peché R; Schlesser M; Verleden G; Vincken W
Respir Med; 2015 Nov; 109(11):1430-8. PubMed ID: 26439177
[TBL] [Abstract][Full Text] [Related]
33. Considerations for Optimal Inhaler Device Selection in Chronic Obstructive Pulmonary Disease.
Dhand R; Cavanaugh T; Skolnik N
Cleve Clin J Med; 2018 Feb; 85(2 Suppl 1):S19-S27. PubMed ID: 29494329
[No Abstract] [Full Text] [Related]
34. Demystifying Dry Powder Inhaler Resistance with Relevance to Optimal Patient Care.
Capstick TGD; Gudimetla S; Harris DS; Malone R; Usmani OS
Clin Drug Investig; 2024 Feb; 44(2):109-114. PubMed ID: 38198116
[TBL] [Abstract][Full Text] [Related]
35. Inhalation device options for the management of chronic obstructive pulmonary disease.
DePietro M; Gilbert I; Millette LA; Riebe M
Postgrad Med; 2018 Jan; 130(1):83-97. PubMed ID: 29210318
[TBL] [Abstract][Full Text] [Related]
36. Inhaler usability of a pressurized metered dose inhaler and a soft mist inhaler in patients with COPD: A simulated-use study.
Ding B; Siddiqui S; DePietro M; Petersson G; Martin UJ
Chron Respir Dis; 2019; 16():1479972318787914. PubMed ID: 30016880
[TBL] [Abstract][Full Text] [Related]
37. A review of the development of Respimat Soft Mist Inhaler.
Dalby R; Spallek M; Voshaar T
Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of inhaler use in patients with chronic obstructive pulmonary disease.
Lee H; Boo S; Lim Y; Kim S; Kim IA
Clin Nurs Res; 2014 Oct; 23(5):560-74. PubMed ID: 23922162
[TBL] [Abstract][Full Text] [Related]
39. Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease.
Ferguson GT; Dalby RN
Postgrad Med; 2018 Aug; 130(6):515-522. PubMed ID: 29972656
[TBL] [Abstract][Full Text] [Related]
40. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.
Hodder R; Pavia D; Dewberry H; Alexander K; Iacono P; Ponitz H; Beck E
Respir Med; 2005 Sep; 99(9):1087-95. PubMed ID: 15893465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
